Home Biosimilar Antibodies Immunology & Inflammation CD markers inhibitor Linvoseltamab (Anti-BCMA & CD3)
For research use only. Not for use in humans.

Linvoseltamab (Anti-BCMA & CD3)

Synonyms: REGN5458

Linvoseltamab is a human bispecific T-cell engager (BiTE) antibody that targets the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA) and the CD3 antigen on T lymphocytes. It demonstrates significant antitumor activity and high efficacy in patients with late-stage relapsed/refractory multiple myeloma (RRMM). MW: 145.78 KD.

Linvoseltamab (Anti-BCMA & CD3)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 0
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Linvoseltamab is a human bispecific T-cell engager (BiTE) antibody that targets the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA) and the CD3 antigen on T lymphocytes. It demonstrates significant antitumor activity and high efficacy in patients with late-stage relapsed/refractory multiple myeloma (RRMM). MW: 145.78 KD.

Product Details

CAS No. 2408319-25-3
Source CHO
Storage
(From the date of receipt)		 -80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.